
The purpose was to examine the prognostic significance of NB in patients receiving potent dual antiplatelet treatment (DAPT) after acute myocardial infarction and the impact of de-escalation of DAPT on clinical outcomes thereafter. NB occurred in 416 patients (16.7%) after 1 month of ticagrelor-based DAPT. At 1 year, NB was not associated with increased BARC 2, 3, or 5 bleeding and major adverse cardiovascular events. However, patients with NB had an increased risk of BARC 2, 3, or 5 bleeding at 6 months, which diminished over the next 6 months. NB was frequent in patients with acute myocardial infarction on 1-month ticagrelor-based DAPT and was associated with an early increase in bleeding. DAPT de-escalation after NB may reduce bleeding without increasing ischemic events.
Like
Save
Share